• Home
  • HCN Trends
  • Contact Us

Search Articles

Cardiology Covid-19 Dermatology Endocrinology General Interest Hematology Infectious Disease Neurology Oncology Pediatrics Psychiatry Pulmonology Rheumatology Surgery Uncategorized
acetaminophen actemra adverse events anemia antibody anxiety azithromycin bipolar disorder bleeding blog brain tumor breast cancer burnout Cancer capecitabine capmatinib cervical cancer chloroquine chronic pain clinical trials cloroquine CME compensation coronary artery disease coronavirus cost covid-19 death diagnosis doctors dosing drug interactions efficacy erlotinib exercise FDA/regulation fever filters glioblastoma green tea guidelines hemophilia hiv hospital hydroxychloroquine ibrutinib ibuprofen immunity induction chemotherapy infectious disease influenza ipilimumab irinotecan iron-deficiency anemia isn letrozole leukemia Lung cancer malaria mask Masks mbc MDS medical cannabis medical school Medicine mesothelioma metastatic colorectal cancer Myelodysplastic Syndromes myeloid leukemia nivolumab nsclc olaparib osimertinib outcomes pandemic patient safety patients pediatrics perjeta physicians podcast practice practice management prevention procedure prostate cancer radiation remdesivir research/studies respirators respiratory retevmo rucaparib sars SCLC selinexor selpercatinib sorafenib stroke Survival/Mortality symptoms syndrome telemedicine testing therapy thrombosis thyroid cancer time tnbc tocilizumab trastuzumab treatment vaccine venetoclax xpovio

December 28, 2020 | Oncology
2021 Breakthroughs, Examining Tazemetostat; Managing Your Money

M3 10 Breakthrough Treatments That Will Change Medicine in 2021

At the 18th Annual 2020 Medical Innovation Summit, experts led by Will Morris, MD, executive medical director for Cleveland Clinic Innovations, and Akhil Saklecha, MD, managing director of Cleveland Clinic Ventures, recognized the top 10 medical advances for 2021. Drum roll, please! Do you agree with the choices?

Millennium Medical Publishing A Closer Look at Tazemetostat

In June 2020, the US Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik, Epizyme), an oral EZH2 inhibitor for the treatment of adult patients with relapsed/refractory follicular lymphoma. Clinical Advances in Hematology & Oncology takes a closer look at this new treatment through a conversation with Dr. Connie Lee Batlevi from MSKCC.

M3 10 Moves for Money-Savvy Physicians

Investing earlier during your financial trajectory is a good idea: The earlier investments are made, the greater the time value of money. If you are interested in accumulating wealth, it is best to start early and pick some winning strategies. From our friends at MDLinx, here are 10 money moves to consider earlier rather than […]
  • © Healthcare Communications Network
  • Privacy Policy